Clinical trials: High Risk Localised Prostate Carcinoma
Prostatic Neoplasms
Dose Escalation For INtraprostatic LEsions
External beam radiotherapy combined with androgen deprivation therapy is a standard treatment option for localized prostate cancer.
- Trial name
- DEFINE (NCT05851547)
- Testing
- Prostate SBRT with Focal Boost, Triptorelin Injection
- Where
- Canada
- Volunteers
- 54 people
- Sponsor
- Ottawa Hospital Research Institute
Prostate Cancer
Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer
Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles. Prostatectomy 2-8 weeks after completion(standard of care and not a part of study)
- Trial name
- NCT00828308
- Testing
- Ixabepilone, Prostatectomy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Brown University
Prostate Cancer, Prostate Adenocarcinoma
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy.
- Trial name
- NCT05726292
- Testing
- Relacorilant, Enzalutamide, Androgen Deprivation Therapy
- Where
- 4 sites in United States
- Volunteers
- 90 people
- Sponsor
- University of Chicago
Prostate Cancer
Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer
This is a phase I neoadjuvant gene therapy followed by prostatectomy, open-label, dose-escalation trial for prostate cancer patients with high risk of local recurrence after radical prostatectomy.
- Trial name
- NCT01197209
- Testing
- Ad-REIC/Dkk-3
- Where
- United States
- Sponsor
- Momotaro-Gene Inc.
Prostate Cancer, Prostate Adenoma
Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Lymph Node Dissection for Localized Intermediate- and High-risk Prostate Cancer With a Briganti Nomogram≥7%
The goal of this clinical trial is to evaluate efficacy and safety of radical prostatectomy (RP) with or without salvage radiotherapy versus RP with extended pelvic lymph node dissection (ePLND) in males who have localized…
- Trial name
- PRESEL (NCT07115992)
- Testing
- RARP±SRT, RARP+ePLND
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Ruijin Hospital
Prostatic Neoplasms
Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
This clinical trial will evaluate the dosimetry, efficacy and toxicity of Lu-PSMA in men with high PSMA-expressing high-risk localized or locoregional advanced prostate cancer (HRCaP) undergoing radical prostatectomy (RP) and…
- Trial name
- LuTectomy (NCT04430192)
- Testing
- 177Lu-PSMA-617
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Prostate Cancer (Adenocarcinoma)
Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer
This study will assess the effects and safety of deutenzalutamide combined with hormone therapy before and after prostate cancer surgery, with docetaxel chemotherapy added before surgery.
- Trial name
- NCT07907653
- Testing
- Deutenzalutamide, Docetaxel, ADT
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Prostate Cancer
Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy
The purpose of this trial is to compare two similar treatments for patients diagnosed with prostate cancer. The two treatment arms being compared are: (Standard Arm) hormone therapy, which will prevent the production of the male…
- Trial name
- NCT00175396
- Testing
- Androgen suppression, radiotherapy, Androgen suppression, radiotherapy, iodine 125 brachytherapy
- Where
- Canada
- Volunteers
- 400 people
- Sponsor
- University of British Columbia
Prostate Cancer
A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
The purpose of this study is to find out whether BMS986365 in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects…
- Trial name
- NCT07335796
- Testing
- BMS-986165, Degarelix
- Where
- 6 sites in United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone
This study investigates neoadjuvant TAK-700 orteronel for 6 months prior to prostatectomy. The three year biochemical free survival is the primary endpoint.
- Trial name
- NEPTUNE (NCT03211052)
- Testing
- TAK-700 and LHRH agonist, prostatectomy
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Centre of Experimental Medicine
Male Erectile Disorder, Prostate Cancer
Focal Therapy for Prostate Cancer Using HIFU
RATIONALE: Prospective trials using hemi-ablation with high intensity focused ultrasound (HIFU) (Sonablate 500) have demonstrated feasibility, safety, and encouraging functional outcomes and early cancer control with 90% of men…
- Conditions
- Male Erectile Disorder, Prostate Cancer, Therapy-related Toxicity, Urinary Incontinence
- Trial name
- INDEX (NCT01194648)
- Testing
- questionnaire administration, assessment of therapy complications, high-intensity focused ultrasound ablation
- Where
- United Kingdom
- Volunteers
- 354 people
- Sponsor
- University College, London
Prostate Cancer
Tumor-directed Radiation Therapy for Patients With the Highest Risk Category of Localized Prostate Cancer
HYPO-RT-PC boost is is an open-label, multicentre, phase II trial evaluating safety and efficacy of real-time image-guided tumor-directed ultra-hypofractionated radiation boost and lymph node irradiation for patients with…
- Trial name
- NCT06220435
- Testing
- Ultra-hypofractionated radiotherapy regimen.
- Where
- 2 sites in Sweden
- Volunteers
- 76 people
- Sponsor
- Region Skane
Prostate Cancer
Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer
The purpose of this study is to see whether immunotherapy with BMS-986218 added to degarelix (which suppresses testosterone) given prior to surgery can decrease the chance that cancer will come back compared to degarelix alone.
- Trial name
- Neo-Red-P (NCT04301414)
- Testing
- BMS-986218 and Degarelix, Degarelix
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Columbia University
Prostate Cancer
Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NRR (NCT00225420)
- Testing
- docetaxel, leuprolide acetate, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Prostate Cancer
Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer
The purpose of this study is to evaluate the incidence of urinary and rectal acute side effects of a pelvic and prostatic intensity-modulated arctherapy with simultaneous integrated boost (SIB-IMRT)combined with long-term…
- Trial name
- NCT01704027
- Testing
- Simultaneous integrated boost intensity-modulated arctherapy, Androgen deprivation
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Centre Georges Francois Leclerc
Neoadjuvant Therapy
A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer
To evaluate the pathological response rate of pamiparib combined with abiraterone acetate in neoadjuvant therapy for surgically resectable high-risk or very high-risk prostate cancer after radical prostatectomy
- Trial name
- NCT05376722
- Testing
- pamiparib, abiraterone, prednisone
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Hongqian Guo
High Risk Localised Prostate Carcinoma
Neo-adjuvant Abiraterone Prostate Study
The role of this study is to focus on the potential role of abiraterone acetate in treatment-naive patients newly diagnosed with high-risk localised prostate cancer requiring combined hormonal therapy and radiotherapy.
- Trial name
- NCT02160353
- Testing
- Abiraterone acetate, Prednisolone
- Where
- 3 sites in Ireland
- Volunteers
- 45 people
- Sponsor
- Cancer Trials Ireland
Prostate Cancer
Hypofractionated Boost vs Conventionally Fractionated Boost for Localized High Risk Prostate Cancer
Randomized trial comparing 2 external beam radiotherapy fractionation schemes in patients with localized high risk prostate cancer. Primary endpoint is acute toxicity.
- Trial name
- NCT03526510
- Testing
- Conventionally Fractionated versus Hypofractionated Boost
- Where
- Canada
- Volunteers
- 178 people
- Sponsor
- Dr. Patrick Cheung
Prostate Cancer
Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer
The aim of the focal treatment HIFU is to destroy the cancer without causing side effects in contrast to radical treatments. Radical treatments (surgery or radiation therapy) are the standard therapies for patient with…
- Trial name
- FOCALE (NCT03568188)
- Testing
- treatment with focal HIFU, PSA dosage, MRI
- Where
- 14 sites in France
- Volunteers
- 174 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada
This is an investigational study on the use of high intensity focused ultrasound (HIFU) in the management of localized prostate cancer (T1c/T2a) as a primary non-comparative study.
- Trial name
- NCT00573586
- Testing
- Sonablate 500 (SB-500)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- SonaCare Medical